FDA Denies Additional China-Developed Oncology Drugs Seeking U.S. Approval: Key Considerations for Future Product Development

Regulatory Clinical Trials Drug Approval FDA ODAC

A Change in Course: FDA Requires Randomized Data to Support PI3K Inhibitor Approvals in Hematologic Malignancies

Data Regulatory